Court invalidates Pfizer’s reissue patent for Celebrex

The company’s exclusivity will now expire 18 months earlier, on May 30, 2014

Painkiller Celebrex has been an incredible moneymaker for pharmaceutical producer Pfizer Inc., partially because of patents that guaranteed Pfizer’s U.S. exclusivity of the drug. However, after a recent district court ruling, that exclusivity may be ending quicker than the company expected.

On March 12, the U.S. District Court for the Eastern District of Virginia invalidated a reissue patent that would have extended Pfizer’s exclusive rights to the drug by 18 months. The original reissue patent was granted by the U.S. Patent and Trademark Office in 2013 and covered various methods of treating osteoarthritis and other conditions through celecoxib, the drug’s active ingredient.

Assistant Editor

author image

Zach Warren

Zach Warren is Assistant Editor of InsideCounsel magazine, where he oversees online content submissions and administers InsideCounsel's enewsletters. Zach specializes in new media and multimedia...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.